Slides
Page 1
Q3 2025 earnings presentation Making Life Better
Page 2
2 Forward-looking statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to expectations of Ingersoll Rand Inc. (the “Company” or “Ingersoll Rand”) regarding the performance of its business, its financial results, its liquidity and capital resources and other non-historical statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “forecast,” “outlook,” “target,” “endeavor,” “seek,” “predict,” “intend,” “strategy,” “plan,” “may,” “could,” “should,” “will,” “would,” “will be,” “on track to” “will continue,” “will likely result,” “guidance” or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. All statements other than historical facts are forward-looking statements. These forward-looking statements are based on Ingersoll Rand’s current expectations and are subject to risks and uncertainties, which may cause actual results to differ materially from these current expectations. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. The inclusion of such statements should not be regarded as a representation that such plans, estimates or expectations will be achieved. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include, among others, (1) adverse impact on our operations and financial performance due to geopolitical tensions, natural disaster, catastrophe, global pandemics, cyber events, or other events outside of our control; (2) unexpected costs, charges or expenses resulting from completed and proposed business combinations; (3) uncertainty of the expected financial performance of the Company; (4) failure to realize the anticipated benefits of completed and proposed business combinations; (5) the ability of the Company to implement its business strategy; (6) difficulties and delays in achieving revenue and cost synergies; (7) inability of the Company to retain and hire key personnel; (8) evolving legal, regulatory and tax regimes; (9) changes in general economic and/or industry specific conditions; (10) actions by third parties, including government agencies; and (11) other risk factors detailed in Ingersoll Rand’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), as such factors may be updated from time to time in its periodic filings with the SEC, which are available on the SEC’s website at http://www.sec.gov. The foregoing list of important factors is not exclusive. Any forward-looking statements speak only as of the date of this presentation. Ingersoll Rand undertakes no obligation to update any forward-looking statements, whether as a result of new information or developments, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Non-GAAP Financial Measures Included in this presentation are certain non-GAAP financial measures designed to supplement, and not substitute, the financial information provided in accordance with generally accepted accounting principles (“GAAP”) in the United States of America because management believes such measures are useful to investors. The reconciliation of those measures to the most comparable GAAP measures for historical periods is set forth in the appendix to this presentation. Reconciliations of non-GAAP measures related to full-year 2025 guidance have not been provided due to the unreasonable efforts it would take to provide such reconciliations due to the high variability, complexity and uncertainty with respect to forecasting and quantifying certain amounts that are necessary for such reconciliations, including net income (loss) and adjustments that could be made for acquisitions-related expenses, restructuring and other business transformation costs, gains or losses on foreign currency exchange and the timing and magnitude of other amounts in the reconciliation of historic numbers. For the same reasons, we are unable to address the probable significance of the unavailable information, which could have a potentially unpredictable, and potentially significant, impact on our future GAAP financial results.
Page 3
3 Premier growth compounder with iconic brands and market leading positions We are a 01 Continued confidence in our trajectory 02 03 3 Staying nimble through our competitive differentiator, IRX Year-to-date organic orders growth, coupled with a year-to-date book-to-bill of 1.04x, position us well for future growth. We remain disciplined in our approach to M&A. Our acquisition pipeline is strong and is primarily focused on targeted bolt-on opportunities. Focused on controlling what we can control in a continuing dynamic environment. Robust M&A funnel enabling future inorganic growth
Page 4
4 We are committed to our disciplined M&A strategy Acquiring market leading products and technologies, focused on bolt-on acquisitions 4 1 As of October 31, 2025. Q3 Highlight: Dave Barry Plastics Acquisition funnel update1 Description: A leading manufacturer of custom clean room solutions, engineered to minimize contamination risks during manufacturing, packaging, and storage processes Annual Revenue: ~$8M Purchase Multiple: High single-digits Headquarters: Dungarvan, Ireland Close: August 1, 2025 Segment: P&ST Rationale: Enhances our capabilities in life science applications for custom plastic products within the biopharmaceutical, pharmaceutical, and medical device industries 9 Additional transactions at LOI stage 200+ Companies currently in the funnel ~90% Deals internally sourced Year-to-date key metrics1 14 Transactions closed ~$250M Expected annualized inorganic revenue acquired ~9.5x Pre-synergy Adjusted EBITDA purchase multiple 400-500bps Expected annualized inorganic revenue to be acquired in 2025
Page 5
5 5 1 Non-GAAP measure (Definitions and/or reconciliations in appendix). 2 Adjusted Diluted EPS and Adjusted EPS defined as (Adjusted Net Income Attributable to Ingersoll Rand Inc.) / (Diluted Average Shares Outstanding). Orders Revenue Adj. EBITDA & Margin1 Adj. Diluted EPS1,2 Up 8% Up 5% Up 2%, down 70 bps Up 2% Q3 2025 vs. Q3 2024 financial performance ($M, excl. EPS) • Q3 organic orders growth of 2% • Backlog up LSD sequentially and up LDD YoY • Q3 book-to-bill of 0.99x; YTD 1.04x • Adjusted EBITDA margin decreased compared to 2024 primarily due to: • organic volume declines • dilutive impact of tariffs • Adjusted EPS up 2% YoY (on top of 9% Adj. EPS growth in Q3’24)
Page 6
6 ($35) 4 1 Non-GAAP measure (Definitions and/or reconciliations in appendix). • YTD free cash flow approximately flat year over year • Total available liquidity of $3.8B including: • Cash and cash equivalents: $1.2B • Available revolving credit facility balance: $2.6B • Liquidity decreased $0.1B versus prior quarter, driven primarily by cash outflows of: • $249M deployed to M&A • $193M in share repurchases; representing ~2.5M shares • $8M through dividend payment Liquidity and Leverage Free Cash Flow1 ($M) Leverage Cash Flows from Operations less Capex (Net Debt / LTM Adjusted EBITDA) Q3 2025 financial performance
Page 7
7 • Book-to-bill of 0.99x; YTD book-to-bill of 1.04x • Organic order growth of low single-digits; third consecutive quarter of positive organic order growth • Adjusted EBITDA margin down year over year, driven by: • Flow-through on organic volume • Impact of tariffs • Continued commercial investments for growth Q3 product line highlights1: (as reported) • Compressor orders up high single-digits • Industrial blower and vacuum orders up low single-digits • Power Tools and Lifting orders up low single-digits Highlights Innovation in Action 4 5Current Year Prior Year YoY ∆ Ex-FX YoY ∆ Revenue $1,540.5 $1,467.2 5.0% 3.5% Adj. EBITDA $447.5 $449.9 (0.5)% — Adj. EBITDA Margin 29.0% 30.7% (170)bps — Organic FX M&A YoY ∆ Orders Growth 0.3% 1.5% 5.4% 7.2% Revenue Growth (2.1)% 1.5% 5.6% 5.0% Q3 2025 vs. Q3 2024 Revenue/Orders BridgeQ3 2025 vs. Q3 2024 ($M) Industrial Technologies and Services Broad range of compressor, vacuum, blower, and air treatment solutions as well as industrial technologies including power too ls and lifting equipment 1 Compressors include oil lubricated, oil free, reciprocating and centrifugal offerings; Industrial Vacuum & Blowers include al l blower/vacuum offerings and Nash/Garo products. 2 As compared to previous models. New META 45 – 45 Kw Contact Cooled Compressors The next generation of variable speed compressors feature a compact design that delivers best-in-class efficiency, incorporating newly engineered airends, motors, and packaging for enhanced performance. ~14% Reduction in energy consumption2 Up to 11% Increase in volume flow2 Up to 40% Reduced footprint2
Page 8
8 4 5Current Year Prior Year YoY ∆ Ex-FX YoY ∆ Revenue $414.5 $393.8 5.3% 3.4% Adj. EBITDA $127.6 $118.1 8.0% — Adj. EBITDA Margin 30.8% 30.0% 80 bps — Organic FX M&A YoY ∆ Orders Growth 7.3% 1.9% 1.9% 11.1% Revenue Growth 1.7% 1.9% 1.7% 5.3% Q3 2025 vs. Q3 2024 Revenue/Orders BridgeQ3 2025 vs. Q3 2024 ($M) • Book-to-bill of 1.01x; YTD book-to-bill of 1.02x • Organic orders up 7%; organic order growth in both Precision Technologies and Life Science Technologies • Organic revenue up 2%; organic revenue growth in both Precision Technologies and Life Science Technologies • Third consecutive quarter of organic revenue growth in Life Science Technologies • Adj. EBITDA margin up 80 bps year over year and up 130 bps sequentially from Q2’25 to Q3’25 Highlights Innovation in Action 1 Management estimate. Precision and Science Technologies Mission-critical precision liquid, gas, air, and powder handling technologies for life sciences and industrial applications as well as aerospace and defense applications Flexan delivers customer productivity while maintaining supply chain continuity • A major medical device OEM outsourced the manufacturing of their mission-critical Class III implantable silicone-based devices to Flexan • Chosen for its expertise, Flexan managed the transfer of over 140 SKUs, extensive equipment, molds, and documentation on schedule with zero disruption to downstream manufacturing or patient care supply chains • Product yield rates improved significantly from 55% to over 90%1, delivering productivity gains for the customer Automated Assembly Cell for Implant Device Assembly
Page 9
9 Revised guidance as of 10/30/25 Key Metrics Revenue - Total Ingersoll Rand2 4-6% Ingersoll Rand (Organic)3 (2)-0% Industrial Technologies and Services (Organic) (2)-0% Precision and Science Technologies (Organic) (2)-0% FX Impact4 ~1% M&A5 ~$415M / ~6% Corporate Costs (~$140M) Adjusted EBITDA3 $2,060M - $2,090M (+2% - +4% YoY) Adjusted EPS3 $3.25 - $3.31 ((1%) - +1% YoY) Full-year 2025 changes vs. previous guidance: • Total revenue expectation unchanged; no changes to organic volume expectations • Mid-point of Adj. EBITDA guidance reduced to $2,075M from $2,130M attributable to: • The effect of incremental section 232 tariffs and other tariff increases announced in August • Pricing actions have been executed to offset these incremental tariffs with an expected realization in 2026 • Delayed realization of in-year pricing actions due to backlog growth • Partially offset by lower corporate costs largely reflecting incentive compensation adjustments aligned with performance • Mid-point of Adj. EPS guidance reduced to $3.28 from $3.40 Full-year assumptions: • Gross interest expense: ~$250M; Net interest expense: ~$220M • Adj. tax rate: ~23.5% • Capex: ~2% of revenue • Share count: ~402M • FCF3 to Adj. Net Income conversion: ~100% 1 See slide 2 regarding non-GAAP financial measures.2 All revenue outlook commentary expressed in percentages and based on growth as compared to 2024. 3 Non-GAAP measure (definitions and/or reconciliations in appendix). 4 Based on September 2025 FX rates; does not include the impact of FX on M&A. 5 Reflects revenue from all completed and closed M&A transactions as of October 30, 2025. 2025 full-year guidance1
Page 10
10 Remain nimble in what continues to be a dynamic global environment ▪ We will further leverage our robust global in-region, for-region manufacturing capabilities while opportunistically pivoting to favorable end markets Continuing to differentiate Ingersoll Rand as an investment: ▪ Proven track record of agility and performance ▪ Execute on the multiple levers available to deliver market outperformance Executing on strategic opportunities supported by ample liquidity and strong balance sheet Disciplined and comprehensive capital allocation strategy compounds earnings and continues to deliver durable value creation for our shareholders IRX is our backbone and continues to enable outperformance across the organization Key Takeaways Investing with Ingersoll Rand 10
Page 11
Appendix
Page 12
12 Q3 2025 financial performance – As Reported ($M, excl. EPS) Net Income1 Diluted EPS2 Up 10% Up $0.07 1 Net Income as reported defined as Net Income Attributable to Ingersoll Rand Inc. 2 Diluted EPS defined as (Net Income Attributable to Ingersoll Rand Inc.) / (Diluted Average Shares Outstanding).
Page 13
13 Non-GAAP measures of financial performance In addition to consolidated GAAP financial measures, Ingersoll Rand reviews various non-GAAP financial measures, including “Organic Revenue Growth/(Decline),” “Adjusted EBITDA,” “Adjusted EBITDA Margin,” “Adjusted Net Income,” “Adjusted Net Income Attributable to Ingersoll Rand Inc.,” “Adjusted Diluted EPS,” “Free Cash Flow,” a nd “Free Cash Flow Margin.” Ingersoll Rand believes Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Net Income Attributable to Ing ersoll Rand Inc., and Adjusted Diluted EPS are helpful supplemental measures to assist management and investors in evaluating the Company’s operating results as they exclude certain items that are unusual in nature or whose fluctuation from period to period do not necessarily correspond to changes in the operations of Ingersoll Rand’s business. Ingersoll Rand believes Organic Revenue Growth/(Decline) is a helpful supplemental measure to assist management and investors in evaluating the Company’s operating results as it excludes the impact of foreign currency and acquisitions on revenue growth. Adjusted EBITDA represents net income before interest, taxes, depreciation, amortization and certain non-cash, non-recurring and other adjustment items. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Revenue. Adjusted Net Income is defined as net income including interest, depreciation and amortization of non-acquisition related intangible assets and excluding other items used to calculate Adjusted EBITDA and further adjusted for the tax effect of these exclusions. Adjusted Net Income Attributable to Ingersoll Rand Inc. is defined as Adjusted Net Income less net income attributable to noncontrolling interest. Adjusted Diluted EPS is defined as Adjusted Net Income Attributable to Ingersoll Rand Inc. divided by Adjusted Diluted Average Shares Outstanding. Organic Revenue Growth/(Decline) is defined as As Reported Revenue growth less the impacts of Foreign Currency and Acquisitions. Ingersoll Rand believes that the adjustments applied in presenting Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income Attributable to Ingersoll Rand Inc. are appropriate to provide additional information to investors about certain material non-cash items and about non-recurring items that the Company does not expect to continue at the same level in the future. Incrementals/Decrementals are defined as the change in Adjusted EBITDA versus the prior year period divided by the change in revenue versus the prior year period. Ingersoll Rand uses Free Cash Flow and Free Cash Flow Margin to review the liquidity of its operations. Ingersoll Rand measures Free Cash Flow as cash flows from operating activities less capital expenditures. Free Cash Flow Margin is defined as Free Cash Flow divided by Revenue. Ingersoll Rand believes Free Cash Flow and Free Cash Flow Margin are useful supplemental financial measures for management and investors in assessing the Company’s ability to pursue business opportunities and investments and to service its debt. Free Cash Flow is not a measure of our liquidity under GAAP and should not be considered as an alternative to cash flows from operating activities. Management and Ingersoll Rand’s board of directors regularly use these measures as tools in evaluating the Company’s operating and financial performance and in establishing discretionary annual compensation. Such measures are provided in addition to and should not be considered to be a substitute for, or superior to, the comparable measures under GAAP. In addition, Ingersoll Rand believes that Organic Revenue Growth/(Decline), Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Net Income Attributable to Ingersoll Rand Inc., Adjusted Diluted EPS, Incrementals/Decrementals, Free Cash Flow and Free Cash Flow Margin are frequently used by investors and other interested parties in the evaluation of issuers, many of which also present Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Net Income Attributable to Ingersoll Rand Inc., Adjusted Diluted EPS, Free Cash Flow and Free Cash Flow Margin when reporting their results in an effort to facilitate an understanding of their operating and financial results and liquidity. Organic Revenue Growth/(Decline), Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Net Income Attributa ble to Ingersoll Rand Inc., Adjusted Diluted EPS, Free Cash Flow and Free Cash Flow Margin should not be considered as alternatives to revenue growth, net income, diluted earnings per share or any other performance measure derived in accordance with GAAP, or as alternatives to cash flow from operating activities as a measure of our liquidity. Organic Revenue Growth/(Decline), Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Net Income Attributable to Ingersoll Rand Inc., Adjusted Diluted EPS, Free Cash Flow and Free Cash Flow Margin have limitations as analytical tools, and you should not consider such measures either in isolation or as substitutes for analyzing Ingersoll Rand’s results as reported under GAAP. Reconciliations of Organic Revenue Growth/(Decline), Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Net Income Attributable to Ingersoll Rand Inc., Adjusted Diluted EPS, Free Cash Flow and Free Cash Flow Margin to their most comparable U.S. GAAP financial metrics for historical periods are presented in the appendix. Reconciliations of non-GAAP measures related to full-year 2025 guidance have not been provided due to the unreasonable efforts it would take to provide such reconciliations due to the high variability, complexity and uncertainty with respect to forecasting and quantifying certain amounts that are necessary for such reconciliations, including net income (loss) and adjustments that could be made for acquisitions-related expenses, restructuring and other business transformation costs, gains or losses on foreign currency exchange and the timing and magnitude of other amounts in the reconciliation of historic numbers. For the same reasons, we are unable to address the probable significance of the unavailable information, which could have a potentially unpredictable, and potentially significant, impact on our future GAAP financial results. Due to rounding, numbers presented throughout this release may not sum precisely to the totals provided and percentages may not precisely reflect the absolute figures.
Page 14
14 (Unaudited; in millions) For the Three Month Period Ended September 30, For the Nine Month Period Ended September 30, 2025 2024 2025 2024 Revenues $ 1,955.0 $ 1,861.0 $ 5,559.7 $ 5,336.4 Adjusted EBITDA $ 544.6 $ 532.7 $ 1,513.7 $ 1,485.8 Adjusted EBITDA Margin 27.9 % 28.6 % 27.2 % 27.8 % Adjusted Net Income $ 349.2 $ 344.7 $ 967.6 $ 1,005.7 Adjusted Net Income Margin 17.9 % 18.5 % 17.4 % 18.8 % Free Cash Flow 325.5 374.3 758.6 756.7 Free Cash Flow Margin 16.6 % 20.1 % 13.6 % 14.2 % Adjusted Financial Information
Page 15
15 Reconciliation of Net Income to Adjusted Net Income and Adjusted Diluted Earnings per Share
Page 16
16 Reconciliation of Net Income to Adjusted EBITDA and Adjusted Net Income and Cash Flow from Operating Activities to Free Cash Flow
Page 17
17 Orders & Revenue by Segment and Reconciliation of Segment Adjusted EBITDA to Net Income
Page 18
18 (Unaudited) For the Three Month Period Ended September 30, 2025 Orders Revenue Ingersoll Rand Organic growth (decline) 1.7% (1.3%) Impact of foreign currency 1.6% 1.6% Impact of acquisitions 4.7% 4.7% Total orders and revenue growth 8.0% 5.0% Industrial Technologies & Services Organic growth (decline) 0.3% (2.1%) Impact of foreign currency 1.5% 1.5% Impact of acquisitions 5.4% 5.6% Total orders and revenue growth 7.2% 5.0% Precision & Science Technologies Organic growth 7.3% 1.7% Impact of foreign currency 1.9% 1.9% Impact of acquisitions 1.9% 1.7% Total orders and revenue growth 11.1% 5.3% 1 Organic growth/(decline), impact of foreign currency, and impact of acquisitions are non-GAAP adjustments. References to “impact of acquisitions” refer to GAAP sales from acquired businesses recorded prior to the first anniversary of the acquisition. The portion of GAAP revenue attributable to currency translation is calculated as the difference between (a) the period-to-period change in revenue (excluding acquisition sales) and (b) the period-to-period change in revenue (excluding acquisition sales) after applying prior year foreign exchange rates to the current year period. Orders and revenue growth/(decline) by Segment1